Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human Rhinovirus-A1 as an Expression Vector.

Khamis Tomusange1, Danushka Wijesundara2, Eric James Gowans2

  • 1Virology Laboratory, Basil Hetzel Institute, Discipline of Surgery, University of Adelaide, Woodville Road, Woodville South, Adelaide, SA, 5011, Australia. khamis.tomusange@adelaide.edu.au.

Methods in Molecular Biology (Clifton, N.J.)
|April 5, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD56<sup>bright</sup>NK cells are negatively associated with antibody response to vaccination in people with multiple sclerosis on B-cell-depleting therapy.

Clinical & translational immunology·2026
Same author

Multi-antigen DNA vaccine targeting non-structural proteins confers robust T Cell-mediated protection against Zika virus.

NPJ vaccines·2026
Same author

Evidence from COVID-19 Patients and Murine Studies for a Continuing Trend Towards Targeting of Nasopharyngeal Ciliated Epithelial Cells by SARS-CoV-2 Omicron Sublineages.

Viruses·2025
Same author

Thermostable unit solid dose formulations for subcutaneous administration of DNA vaccines.

Molecular therapy. Nucleic acids·2025
Same author

Mechanistic Target of Rapamycin Inhibitors and Vaccine Response in Kidney Transplant Recipients.

Journal of the American Society of Nephrology : JASN·2025
Same author

Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis.

mAbs·2025

Researchers developed a new method to create genetically stable, replication-competent human rhinovirus (HRV) vectors for vaccines. These novel recombinant HRVs (rHRVs) can carry foreign genes, overcoming previous limitations in vaccine development.

Area of Science:

  • Virology and Vaccine Development
  • Molecular Biology and Genetic Engineering

Background:

  • Live human rhinovirus (HRV) expression vectors are promising for vaccines but limited by foreign gene capacity and genetic instability.
  • Previous HRV-based vectors faced challenges in reliably expressing foreign genetic material for therapeutic or vaccine purposes.

Purpose of the Study:

  • To engineer a novel methodology for creating replication-competent and genetically stable recombinant human rhinovirus (rHRV).
  • To overcome the limitations of existing HRV vectors for vaccine development, specifically regarding genetic stability and insert capacity.

Main Methods:

  • Development of a novel genetic engineering technique to modify the HRV genome.
  • Ensuring the engineered rHRV maintains replication capability post-modification.
Keywords:
HIV-Gag and HIV-TatHRV-A1Live vaccine vector

Related Experiment Videos

  • Generation of live, genetically stable rHRVs encoding specific foreign proteins (e.g., HIV Gag and Tat).

    • Main Results:

    • Successfully engineered a replication-competent and genetically stable rHRV.
    • Demonstrated the ability to generate rHRVs encoding foreign proteins, such as HIV Gag and Tat (rHRV-Gag-Tat).
    • The novel rHRV platform maintained viral replication capabilities after genetic modification.

    Conclusions:

    • A new methodology enables the creation of genetically stable, replication-competent rHRVs.
    • These engineered rHRVs, like rHRV-Gag-Tat, represent a potential platform for developing mucosally targeted vaccines, including for HIV.
    • The developed rHRV system addresses key limitations, enhancing the feasibility of HRV-based vaccine strategies.